|
|
Volumn 10, Issue 8, 2014, Pages 443-
|
|
Rheumatoid arthritis: Can tofacitinib be used as first-line monotherapy for RA?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
METHOTREXATE;
TOFACITINIB;
ANTIRHEUMATIC AGENT;
PIPERIDINE DERIVATIVE;
PYRIMIDINE DERIVATIVE;
PYRROLE DERIVATIVE;
DISEASE COURSE;
DRUG COST;
DRUG EFFICACY;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
ERYTHROCYTE SEDIMENTATION RATE;
GASTROINTESTINAL DISEASE;
HERPES ZOSTER;
HUMAN;
MONOTHERAPY;
NOTE;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
REMISSION;
RHEUMATOID ARTHRITIS;
SYMPTOMATOLOGY;
ARTHRITIS, RHEUMATOID;
FEMALE;
MALE;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
FEMALE;
HUMANS;
MALE;
METHOTREXATE;
PIPERIDINES;
PYRIMIDINES;
PYRROLES;
|
|
EID: 84905444619
PISSN: 17594790
EISSN: 17594804
Source Type: Journal
DOI: 10.1038/nrrheum.2014.108 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|
